• Invasive fungal infections caused by Aspergillus are one of the main
causes of morbidity and mortality in immunocompromised patients • Examples: bone marrow transplant recipients and those undergoing treatment for haematological malignancies. The patients at the highest risk are those with prolonged neutropenia.
• The mortality rate aspergilosis is very high 80%–95%, Difficulties
of diagnosing (IA) nonspecific and late clinical signs & insensitivity of conventional laboratory diagnostic. • Early diagnosis is important, and sensitive molecular assays have the potential to improve diagnosis.
• Diagnostic procedures include blood cultures for certain molds;
cultures, histopathological, and microscopic examinations of appropriate diagnostic specimens; and imaging studies guided by clinical findings. But the problem is the difficulties of obtaining an adequate specimen, long-term cultures, and negative or delayed results limit efficient and rapid microbiological diagnosis. 2 laboratorys test before molecular testing: - Modern imaging techniques such as high-resolution computed tomography (HRCT) can detect early signs that are consistent with pulmonary aspergillosis (‘halo sign’ and macronodules) Not specific. - Galactomannan (GM) antigen test more than specific for detection of circulating fungal cell wall components and fungal nucleic acids in the blood and other body fluids Objective • In two decades, molecular diagnostic techniques have been developed for IA, including polymerase chain reaction (PCR)
• this studywill bw evaluate the diagnostic potential of GM and real-
time PCR assay for IA diagnosis. Material and method
Study design
- January 2011 and January 2012; febrile neutropenic patients with
haematologic malignancies were included in the present study. • Criteria of neurtopenic: fever >38.5 °C and absolute neutrophil count of < 0,5 x 10 −9 Serum samples were obtained twice weekly from patients at increased risk of developing IA. • Samples obtained from each patient with febrile neutropenic episode at a risk of IA were tested by realtime PCR, both MAP and IHP tests, to investigate the presence of Aspergillus DNA, and by ELISA to detect the GM antigen. DNA extraction from serum specimens
• What the steps?
- Performed in a Class II laminar flow cabinet .
- DNA extraction from serum samples was performed using a QIAamp DNA mini kit (Qiagen, Hilden, Germany). - One negative control was included in each extraction procedure. - The extraction performance was monitored by testing both blinded and known simulated positive control specimens. - DNA samples were stored at 20 °C until PCR analysis. DNA amplification and detection
• Use In vitro diagnostic test, MAP (Myconostica Ltd, Manchester, UK)
based on molecular beacon real time PCR technology that targets the multi-copy 18S rRNA gene included an internal amplification control.
• PCR positivity was determined using a threshold of 39 cycles that
corresponded to a target sensitivity of ≤50 DNA copies, which was approximately equivalent to one A. fumigatus genome. In-house real-time PCR
• The IHP test was performed using a real-time PCR Mastermix
synthesized by Primer design (Southampton, UK).
• Used for IHP, which targeted the 28S rRNA, with 10 ll of the DNA template in a final reaction volume of 50 ll.
• The amplification was performed using the following conditions: a 10
s denaturation step at 95 °C followed by 45 cycles of denaturation at 95 °C (15 s), annealing at 60 °C (60 s), and polymerization at 72 °C (20 s). GM antigent test
• Sandwich ELISA for serum GM detection (Platelia Aspergillus; Bio-Rad,
Marnes-la-Coquette, France). The results were considered positive if the optical index value in serum samples was ≥0.5. Statistic analysis
• The associations between baseline patient characteristics and the
assay results were analysed using Fisher’s exact test, Wilcoxon’s rank- sum test, and the Mann–Whitney U-test. All tests were two-sided, and a P value of<0.05 was considered statistically significant. Analyses were performed using SPSS